These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The new beta-adrenergic antagonists. Chung DC; Laschuk MJ Can Anaesth Soc J; 1984 Jul; 31(4):430-3. PubMed ID: 6146393 [No Abstract] [Full Text] [Related]
5. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. Jack DB; Kendall MJ; Dean S; Laugher SJ; Zaman R; Tenneson ME Biopharm Drug Dispos; 1982; 3(1):47-54. PubMed ID: 6123352 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients. Dreyfuss J; Griffith DL; Singhvi SM; Shaw JM; Ross JJ; Vukovich RA; Willard DA J Clin Pharmacol; 1979; 19(11-12):712-20. PubMed ID: 43870 [No Abstract] [Full Text] [Related]
7. Nadolol in human serum and breast milk. Devlin RG; Duchin KL; Fleiss PM Br J Clin Pharmacol; 1981 Sep; 12(3):393-6. PubMed ID: 6117304 [TBL] [Abstract][Full Text] [Related]
8. Nadolol: placental transfer and excretion in the milk of rats. Dreyfuss J; Shaw JM; Miller TJ Toxicol Appl Pharmacol; 1977 Feb; 39(2):275-82. PubMed ID: 15333 [No Abstract] [Full Text] [Related]
9. Disposition of [14C]nadolol in dogs with reversible renal impairment induced by uranyl nitrate. Singhvi SM; Heald AF; Murphy BF; DiFazio LT; Schreiber EC; Poutsiaka JW Toxicol Appl Pharmacol; 1978 Jan; 43(1):99-109. PubMed ID: 24287 [No Abstract] [Full Text] [Related]
10. Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: an unusual species difference. Dreyfuss J; Shaw JM; Ross JJ Xenobiotica; 1978 Aug; 8(8):503-8. PubMed ID: 29379 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol. Regårdh CG Acta Pharmacol Toxicol (Copenh); 1975; 37(1):1-39. PubMed ID: 237402 [No Abstract] [Full Text] [Related]
13. Metabolic studies in patients with nadolol: oral and intravenous administration. Dreyfuss J; Brannick LJ; Vukovich RA; Shaw JM; Willard DA J Clin Pharmacol; 1977; 17(5-6):300-7. PubMed ID: 16040 [TBL] [Abstract][Full Text] [Related]
14. Effects of a meal and its composition on the bioavailability of betaxolol administered orally to healthy subjects. Thiercelin JF; Bianchetti G; Larribaud J; Ganansia J; Deves C; Trocherie S; Abriol C; Morselli PL World Rev Nutr Diet; 1984; 43():183-6. PubMed ID: 6147938 [No Abstract] [Full Text] [Related]
15. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Heel RC; Brogden RN; Pakes GE; Speight TM; Avery GS Drugs; 1980 Jul; 20(1):1-23. PubMed ID: 6105067 [TBL] [Abstract][Full Text] [Related]
16. Determination of orally coadministered nadolol and its deuterated analogue in human serum and urine by gas chromatography with selected-ion monitoring mass spectrometry. Cohen AI; Devlin RG; Ivashkiv E; Funke PT; McCormick T J Pharm Sci; 1984 Nov; 73(11):1571-5. PubMed ID: 6151597 [TBL] [Abstract][Full Text] [Related]